News

Filter

Current filters:

Opdivo

1 to 9 of 19 results

Most promising drugs of 2015 identified in new report

23-03-2015

Annual forecast finds significant increase in the number of blockbuster drug set to enter this year’s…

Bristol-Myers SquibbGlobalLCZ-696Markets & MarketingNovartisOpdivoPharmaceuticalPraluentRegeneron PharmaceuticalsSanofi

US FDA expands use of Bristol-Myers’ Opdivo to NSCLC

US FDA expands use of Bristol-Myers’ Opdivo to NSCLC

05-03-2015

The US Food and Drug Administration late yesterday expanded the approved use of pharma major Bristol-Myers…

BiotechnologyBristol-Myers SquibbOncologyOpdivoRegulationUSA

Bristol-Myers will lead immuno-oncology market in 2022, say analysts

Bristol-Myers will lead immuno-oncology market in 2022, say analysts

04-03-2015

Analysts at Morningstar Equity Research see significantly more opportunity than the overall market for…

AstraZenecaBiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & CoOncologyOpdivoResearchRoche

Ono signs deal with Dako for Opdivo companion diagnostic test

Ono signs deal with Dako for Opdivo companion diagnostic test

16-02-2015

Japanese pharma company Ono Pharmaceutical and Danish diagnostic provider Dako have signed a new partnership…

BiotechnologyDakoJapanLicensingOncologyOno PharmaceuticalOpdivo

Bristol-Myers stops Opdivo NSCLC study early on good results

12-01-2015

US pharma major Bristol-Myers Squibb says that an open-label, randomized Phase III study evaluating Opdivo…

Bristol-Myers SquibbOncologyOpdivoPharmaceuticalResearch

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

23-12-2014

The US Food and Drug Administration yesterday granted accelerated approval to US pharma major Bristol-Myers…

Bristol-Myers SquibbKeytrudaMerck & CoOncologyOpdivoPharmaceuticalRegulationUSA

1 to 9 of 19 results

Back to top